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In human platelets, serotonin is known to induce a shape change followed by (reversible) aggregation. 
Recently, it was found that the amine triggers the elevation of cytosolic free calcium and activates 
phospholipase C. On stimulation of human platelets with serotonin we found an immediate increase in 
protein kinase C activity, phosphorylating its 40 kDa substrate protein. A 20 kDa protein, most likely the 
myosin light chain, was phosphorylated to the same extent. Ketanserin, a highly selective serotonin-S2 
antagonist inhibited both phosphorylation processes at subnanomolar concentrations. 
Serotonin-S2 receptor Protein phosphorylation Platelet Ketanserin 
1. INTRODUCTION 
In human platelets, serotonin induces a shape 
change followed by (reversible) aggregation [ 11. 
When the cells are prelabelled with [32P]or- 
thophosphate, the addition of the amine results in 
a marked increase in 32P incorporation in PA 
(here, [2]). The potency of several drugs to an- 
tagonize this PA-labelling was found to be directly 
related to their potency to inhibit platelet aggrega- 
tion and to their binding affinities for serotonin-S2 
receptor sites [2]. It was suggested that part of the 
signal transducing system, which follows seroton- 
in-& receptor activation, involves phospholipase C 
catalyzed inositide breakdown (PI response) yield- 
ing diacylglycerol (DAG) which is subsequently 
phosphorylated to PA [2]. 
activating factors [7,8] and arachidonic acid [9]. 
Thrombin and collagen also induce phosphoryla- 
tion of a 20 kDa protein [6,10] that has been iden- 
tified as the myosin light chain [lo]. A specific Ca- 
calmodulin-dependent protein kinase was pro- 
posed to be responsible for this phosphorylation 
[lo]. Here we investigated whether in the intact 
platelet both the endogenous ubstrate for the pro- 
tein kinase C, and the myosin light chain kinase, 
are phosphorylated as a consequence of serotonin- 
S2 receptor activation. 
2. EXPERIMENTAL 
Authors in [3,4] found that the stimulus-evoked 
formation of DAG might serve as a signal for 
transmembrane control of protein phosphoryla- 
tion through the activation of the protein kinase C 
(review [3,4]). In platelets this enzyme was found 
to phosphorylate a 40 kDa protein after stimula- 
tion with thrombin [5], collagen [5,6], platelet- 
Human venous blood was collected from 
healthy volunteers in 0.2 vol. anticoagulant buffer 
containing 1.3% citric acid, 2.5% sodium acetate 
and 20/o dextrose. 
Abbreviations: PA, phosphatidic acid; DAG, 
diacylglycerol 
Platelets were prepared as in [l 11, except for the 
buffers. Washing buffer contained 25 mM Hepes 
(pH 7.2), 125 mM NaCl, 10 mM glucose, 1 mM 
EGTA and 1 mg/ml BSA. Final buffer consisted 
of 25 mM Hepes (pH 7.5), 125 mM NaCl, 2.7 mM 
KCl, 5.6 mM MgS04, 10 mM glucose, 0.1 mM 
EGTA, 1 mg/ml BSA. After addition of carrier 
free [32P]orthophosphate (250 &i/ml platelets), 
the platelet suspension was incubated at 37°C for 
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60 min. Cells were stimulated with serotonin 
creatinine sulfate monohydrate (Janssen Chimica). 
Samples (150 ~1: 4 x 10’ cells) were taken at the 
time indicated and immediately transferred in 
4.5 ml CHCls/CHsOH/0.45 N HC1(20:40: 13, by 
vol.). Two phases were obtained after the addition 
of 1.25 ml CHCls and 1.25 ml 0.1 N HCl. After 
centrifugation the organic phase was washed with 
2.5 ml CHsOH/0.2 N HCl (1: 1) and recentri- 
fuged. The organic phase was evaporated under 
Nz, applied to silica gel 60 precoated plastic sheets 
(E. Merck, Darmstadt, FRG) and eluted in 
CHCls/CHsOH/20% methylamine (60: 35 : 10). 
After autoradiography on Kodak X-Omat R films, 
phosphatidic acid was located on the sheets and cut 
out. Radioactivity was quantitated by liquid scin- 
tillation spectrometry. 
For protein analysis, 80 ~1 samples (2.1 x lo8 
cells) were quenched in a 5 times concentrated sam- 
ple buffer [12] and incubated at 90°C for 5 min. 
Proteins were separated by sodium dodecylsulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) 
on a 12.5% gel using the Laemmli buffers [12]. 
Gels were stained with Coomassie brilliant blue, 
dried and subjected to autoradiography. Areas 
corresponding to the 40 and 20 kDa proteins were 
cut out and radioactivity was determined by liquid 
scintillation counting. 
3. RESULTS AND DJSCUSSION 
On addition of serotonin to human platelets 
prelabelled with [32P]orthophosphate, maximal in- 
crease in [32P]PA was observed at 2-4 X 10m6 M 
amine [2]. Using 4 x 10e6 M serotonin we found 
an increase in 32P-labelled 20 kDa and 40 kDa pro- 
teins (fig.1). Both increases reach their maximal 
phosphorylation, respectively, within 10 and 20 s 
after stimulation after which a decrease to approx. 
20% is observed within 1 and 2 min. Maximal 
40 kDa protein phosphorylation precedes the max- 
imum for [32P]PA formation which is consistent 
with the idea that DAG, the metabolic precursor of 
this phospholipid, is the possible activator of the 
protein kinase C. 
The formation of 32P-labelled 40 kDa and 
20 kDa proteins after serotonin stimulation is 
more transient compared to platelet stimulation 
with potent agonists like thrombin, collagen and 
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Fig.1. Time course of increase in phosphorylation. 
Isolated human platelets prelabelled with [32P]ortho- 
phosphate were stimulated with 4 x 10e6 M serotonin. 
(0) 32P-labelled 20 kDa protein, (0) 32P-labelled 40 kDa 
protein, (0) [32P]phosphatidic acid. Points represent he 
mean of 2 determinations on the same platelet 
preparations. The results are representative of 5 separate 
experiments. 
platelet activating factor [5-8,13,14]. The low 
degree of platelet activation that corresponds with 
a small activation of the phospholipase C [2,13] 
could at least in part be responsible for this obser- 
vation. A similar finding has been reported after 
stimulation of platelets with arachidonic acid 
(0.2pM) another weak agonist [9]. Using this 
stimulus, at least in this concentration, formation 
of [32P]PA (-230% above control) and the time 
course of 40 kDa protein phosphorylation are ap- 
proximately the same as those found with sero- 
tonin (here, [2]). 
Pre-incubation of the platelets with sub- 
nanomolar concentrations of ketanserin dose- 
dependently inhibited the serotonin-stimulated 
32P-labelling of both the 40 and 20 kDa protein 
(fig.2). Inhibition curves coincided with the inhibi- 
tion by ketanserin of serotonin-stimulated 32P- 
labelling of PA (fig.2). The drug concentration re- 
quired to inhibit the biochemical processes 
matched its binding affinity for serotonin-S2 recep- 
tor sites on rat cerebral cortex membranes [ 151, cat 
platelet membranes [16] and human platelet mem- 
branes [17]. Ketanserin has been described as a 
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Fig.2. Dose-dependent inhibition by ketanserin of 
serotonin-induced changes [32P]phosphatidic acid, “P- 
labelled 40 kDa and 20 kDa protein. Isolated human 
platelets labelled with [32P]orthophosphate were pre- 
incubated for 22 min with the appropriate concentration 
of ketanserin. Then serotonin (4 x 10m6 M) was added. 
Samples were taken at 15 s for protein analyses and at 
35 s after stimulation for lipid analysis. (0) 32P-labelled 
20 kDa protein (mean of 4 determinations), (0) “P- 
labelled 40 kDa protein (mean of 4 determinations), (0) 
[32P]phosphatidic acid (mean of 2 determinations). 
Results are representative of 3 separate experiments. 
new serotonin antagonist which binds primarily to 
serotonin-S2 receptor sites; its binding affinity for 
the latter receptor sites (& = 0.4 nM) being at least 
25 times higher than its affinity for other 
neurotransmitter eceptor sites [ 181. At the sub- 
nanomolar ketanserin concentration used here no 
interactions with other receptor sites than the 
serotoninS2 sites are to be expected [181. The drug 
was shown in previous studies not to active on non- 
serotonin dependent human platelet reactions [ 111, 
nor to have any direct effect on the phosphoryla- 
tion systems of the 40 and 20 kDa proteins after 
stimulation with thrombin (1 unit/ml) or ADP 
(10m5 M) (table 1). Therefore it is concluded that 
the decrease in the level of 32P-labelled protein 
after serotonin stimulation in the presence of 
ketanserin is due to a block of the receptor-agonist 
coupling. 
Table 1 
Influence of ketanserin on protein phosphorylation after 




40 kDa (cpm) 20 kDa (cpm) 
275 1?: 15 107 f 2 
(1 unit/ml) 
Thrombin 
3050 f 68 1009 f 23 
(1 unit/ml) + 
ketanserin (lo-’ M) 3118 f 59 1003 f 12 
ADP (lo-’ M) 549 f 11 300+ 6 
ADP (1O-5 M) + 
ketanserin (lo-* M) 520 f 31 315 If: 17 
Isolated human platelets prelabelled with [32P]ortho- 
phosphate were stimulated with thrombin or ADP for 
30 s. The contact time with the drug before stimulation 
was 22 min. Results represent means f SD of triplicate 
samples 
Antagonism of the 40 kDa phosphorylation by 
increasing platelet CAMP levels has been reported 
[4,5,7-91. Such an antagonism does not, however, 
prove the link between the receptor and protein 
phosphorylation since the latter might be directly 
regulated by CAMP levels, neither do experiments 
in which protein phosphorylation could be sup- 
pressed by trifluperazine and dibucaine, since in 
the presence of these drugs the primary 
biochemical events after receptor occupation 
(phospholipase C activation and increase in in- 
tracellular free Ca2’) took place [5,19]. Evidence 
in favour of a direct link between receptor occupa- 
tion and protein phosphorylation was provided by 
the use of a synthetic DAG and the calcium 
ionophore A23187. In these experiments it was 
clearly shown that the products of the early 
biochemical events after receptor-agonist coupl- 
ing, DAG and Ca2+ could independently enhance 
phosphorylation of the 40 and 20 kDa protein; a 
receptor was, however, not involved [20]. 
In conclusion, stimulation of platelets by 
serotonin provides us with a model in which recep- 
tor occupancy, the primary biochemical events 
(phospholipase C activation [2] and intracellular 
free Ca2+ increase [21]) and protein phosphoryla- 
tion are coupled and in which a receptor antagonist 
can stop the cascade of events comprising the 
signal transducing system. 
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